China's Simcere Pharma grants AbbVie option to license its blood cancer drug candidate

Simcere Pharmaceutical

13/01/2025 14:13

Jan 13 (Reuters) - Simcere Pharmaceutical  2096.HK  said
on Monday its unit had granted U.S. drugmaker AbbVie  ABBV.N 
the option to license its new blood cancer drug candidate
outside China.
    Under the deal, AbbVie will pay Simcere up to $1.06 billion,
along with royalties on sales outside China. AbbVie would
receive royalties on sales within China.

 (Reporting by Aaditya Govind Rao in Bengaluru; Editing by Vijay
Kishore)
 ((Aaditya.GovindRao@thomsonreuters.com;))